Ketamine Therapy is Not Advisable for Arthrochalasis EDS
Low-dose ketamine therapy should not be used for arthrochalasis-type Ehlers-Danlos syndrome (aEDS) due to lack of evidence specific to this rare subtype, significant safety concerns with chronic use, and availability of safer alternatives for pain management.
Critical Context: Arthrochalasis EDS is Not Hypermobile EDS
Arthrochalasis EDS (aEDS) is an extremely rare autosomal dominant disorder caused by COL1A1 or COL1A2 gene mutations, with only approximately 42 cases published worldwide 1. This subtype is characterized by severe generalized joint hypermobility, bilateral congenital hip dislocation, skin hyperextensibility, and muscle hypotonia 1. Critically, aEDS is genetically and clinically distinct from hypermobile EDS (hEDS), which accounts for 80-90% of all EDS cases 2.
Why Ketamine is Not Recommended
Lack of Evidence for Arthrochalasis EDS
The available evidence for ketamine use in EDS is limited to:
- One single case report of ketamine infusion in a patient with hEDS and spinal cord ischemic myelopathy causing central pain syndrome 3
- No published data specifically addressing aEDS patients
- The case report involved a 7-day intensive care unit infusion under controlled sedation—not a practical or safe outpatient approach 3
Significant Safety Concerns with Chronic Use
The FDA label explicitly warns about serious complications with chronic ketamine use 4:
- Genitourinary complications: Case reports document genitourinary pain and biliary duct dilatation with recurrent use 4
- Hepatobiliary dysfunction: Cholestatic liver injury pattern with recurrent dosing requires baseline and periodic liver function monitoring 4
- Drug-induced liver injury: Requires monitoring of alkaline phosphatase and gamma glutamyl transferase with recurrent dosing 4
The FDA specifically states: "In individuals with a history of chronic ketamine use for off-label indications, there have been case reports of genitourinary pain that may be related to the ketamine treatment" 4. This is particularly concerning given that EDS patients already experience complex multisystem symptoms.
Ketamine is FDA-Approved Only for Anesthesia
Ketamine hydrochloride injection is FDA-indicated only as:
- A sole anesthetic agent for diagnostic/surgical procedures
- Induction of anesthesia prior to other general anesthetics
- A supplement to other anesthetic agents 4
There is no FDA approval for chronic pain management in any EDS subtype.
Administration Requirements Preclude Outpatient Use
The FDA mandates that ketamine must be:
- Administered by physicians experienced in general anesthetics and airway management
- Given with continuous vital sign monitoring
- Used with immediately available emergency airway equipment 4
These requirements make chronic outpatient ketamine therapy impractical and potentially dangerous.
Safer Evidence-Based Alternatives
For aEDS pain management, current evidence supports 1, 5:
First-line approaches:
- Physical and occupational therapy (rated as highly efficacious by patients) 6
- Transcutaneous electrical nerve stimulation (TENS) units 5
- Trigger point injections (with lidocaine showing efficacy in hEDS) 7
- Low-dose naltrexone 5
Pharmacological options:
- NSAIDs and acetaminophen (used by 70-92% of EDS patients) 6
- Gabapentin or pregabalin for neuropathic components
- Tricyclic antidepressants 3
Multimodal strategies:
- Cognitive behavioral therapy for pain management 5
- Patient education programs 5
- Treatment focused on reducing hypermobility symptoms, central sensitization, and fatigue 5
Important Caveats
If Considering Ketamine Despite Recommendations
Should a provider still consider ketamine in exceptional circumstances:
- Restrict to refractory central neuropathic pain only (as in the single case report) 3
- Require intensive care unit setting with controlled sedation 3
- Obtain baseline liver function tests including alkaline phosphatase and GGT 4
- Monitor for genitourinary symptoms and consider cessation if they develop 4
- Plan for short-term use only (the case report used 7 days) 3
- Never use as first-line therapy
The Evidence Gap
The 2022 comprehensive review on chronic pain in EDS explicitly states: "Research on pain in EDS is still limited with good clinical practice guidelines often limited by poor sample size and lack of clinical studies" 5. With only 42 published cases of aEDS worldwide, extrapolating from a single hEDS case report is scientifically unsound 1.
Mast Cell Considerations
While not specific to aEDS, if mast cell activation syndrome (MCAS) is suspected as a comorbidity, certain medications should be avoided. The 2025 AGA guidelines note that opioids and NSAIDs can trigger MCAS 2. Though ketamine is not specifically mentioned as a trigger, its use in patients with potential MCAS requires additional caution.
The burden of proof for safety and efficacy lies with demonstrating benefit in aEDS specifically—this evidence does not exist. Treatment should focus on established, safer modalities with better risk-benefit profiles.